Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)

TabibianJ.H.; LindorK.D.

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)

【24h】

Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)

机译：原发性硬化性胆管炎中的熊去氧胆酸：如果停药不好，则给药良好（对吗？）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, cholestatic liver disease characterized by biliary inflammation and periductal fibrosis. Unlike most other cholestatic liver diseases, PSC affects individuals of essentially all ages and racial backgrounds, remains etiopathogenically perplexing, and lacks established medical therapy despite extensive laboratory-based investigation, translational research, and clinical trials.It is on this basis that PSC has, regrettably, come to be regarded as the "black box" of liver disease.

机译：原发性硬化性胆管炎（PSC）是一种慢性，特发性胆汁淤积性肝病，其特征是胆道炎症和导管周围纤维化。与大多数其他胆汁淤积性肝病不同，尽管PSC进行了广泛的实验室研究，转化研究和临床试验，但PSC影响着几乎所有年龄和种族背景的个体，在病因上仍然令人困惑，并且缺乏既定的医学治疗方法。遗憾的是，它被视为肝脏疾病的“黑匣子”。

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2014年第3期|共4页
作者
TabibianJ.H.; LindorK.D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?) [J] . TabibianJ.H., LindorK.D. Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2014,第3期

机译：原发性硬化性胆管炎中的熊去氧胆酸：如果停药不好，则给药良好（对吗？）
2. A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis [J] . Dennis D. Black, Cara Mack, Nanda Kerkar, Hepatology communications. . 2019,第11期

机译：儿科初级硬化性胆管炎尿酸胆酸撤退和恢复前瞻性试验
3. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis [J] . WunschE., TrottierJ., MilkiewiczM., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2014,第3期

机译：原发性硬化性胆管炎患者中熊去氧胆酸戒断的前瞻性评估
4. Dose effect of ursodeoxycholic acid used in the treatment of primary biliary cirrhosis and primary sclerosing cholangitis [C] . K. D. LINDO Falk Symposium . 2005

机译：熊毒胆酸的剂量效应用于治疗原发性胆汁肝硬化和原发性胆管炎
5. Predicting outcomes post liver transplantation in patients with primary biliary cirrhosis and primary sclerosing cholangitis. [D] . Zapatochny Rufo, Rebecca Jo. 2003

机译：预测原发性胆汁性肝硬化和原发性硬化性胆管炎患者肝移植后的结局。
6. A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis [O] . Dennis D. Black, Cara Mack, Nanda Kerkar, 2019

机译：小儿原发性硬化性胆管炎戒断和恢复熊去氧胆酸的前瞻性试验
7. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis [O] . Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, 2014

机译：原发性硬化性胆管炎患者尿道氧胆酸脱水的前瞻性评价

Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)

摘要

著录项

相似文献

相关主题

期刊订阅